Targeting Src family kinases in anti-cancer therapies: Turning promise into triumph

Trends in Pharmacological Sciences

Volumn 33, Issue 3, 2012, Pages 122-128

  Zhang, Siyuan ^a   Yu, Dihua ^a  

^a UNIVERSITY OF TEXAS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; BCR ABL PROTEIN; BOSUTINIB; CETUXIMAB; DASATINIB; EPHRIN RECEPTOR A2; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ERLOTINIB; FLUOROURACIL; FOLINIC ACID; MAMMALIAN TARGET OF RAPAMYCIN; OXALIPLATIN; PLATELET DERIVED GROWTH FACTOR RECEPTOR; PROTEIN TYROSINE KINASE; PROTEIN TYROSINE KINASE INHIBITOR; PROTEIN TYROSINE PHOSPHATASE 1B; SARACATINIB; SCATTER FACTOR RECEPTOR; STEM CELL FACTOR RECEPTOR;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER INHIBITION; CANCER RECURRENCE; CANCER RESISTANCE; CASTRATION RESISTANT PROSTATE CANCER; COLON CANCER; DRUG TARGETING; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HEAD AND NECK CANCER; HUMAN; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; METASTASIS POTENTIAL; MONOTHERAPY; PANCREAS CANCER; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION; REVIEW; SIGNAL TRANSDUCTION; STOMACH CANCER; TRIPLE NEGATIVE BREAST CANCER;

ANTINEOPLASTIC AGENTS; CLINICAL TRIALS, PHASE II AS TOPIC; HUMANS; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTEIN KINASE INHIBITORS; SRC-FAMILY KINASES;

EID: 84857916018     PISSN: 01656147     EISSN: 18733735     Source Type: Journal    
DOI: 10.1016/j.tips.2011.11.002     Document Type: Review

References (60)

1. T.J. Yeatman A renaissance for SRC Nat. Rev. Cancer 4 2004 470 480 (Pubitemid 38745532)
2. M.P. Playford, and M.D. Schaller The interplay between Src and integrins in normal and tumor biology Oncogene 23 2004 7928 7946 (Pubitemid 39468852)
3. L.C. Kim Src kinases as therapeutic targets for cancer Nat. Rev. Clin. Oncol. 6 2009 587 595
4. M.A. Eckert Twist1-induced invadopodia formation promotes tumor metastasis Cancer Cell 19 2011 372 386
5. C.S. Pichot Dasatinib synergizes with doxorubicin to block growth, migration, and invasion of breast cancer cells Br. J. Cancer 101 2009 38 47
6. M.A. Matrone Microtentacles tip the balance of cytoskeletal forces in circulating tumor cells Cancer Res. 70 2010 7737 7741
7. E.M. Balzer c-Src differentially regulates the functions of microtentacles and invadopodia Oncogene 29 2010 6402 6408
8. X.H. Zhang Latent bone metastasis in breast cancer tied to Src-dependent survival signals Cancer Cell 16 2009 67 78
9. D. Barkan Metastatic growth from dormant cells induced by a col-I-enriched fibrotic environment Cancer Res. 70 2010 5706 5716
10. Y. Sakuma ABT-263, a Bcl-2 inhibitor, enhances the susceptibility of lung adenocarcinoma cells treated with Src inhibitors to anoikis Oncol. Rep. 25 2011 661 667
11. P. Zhu Angiopoietin-like 4 protein elevates the prosurvival intracellular O2(-):H2O2 ratio and confers anoikis resistance to tumors Cancer Cell 19 2011 401 415
12. M.Z. Noman Blocking hypoxia-induced autophagy in tumors restores cytotoxic T cell activity and promotes regression Cancer Res. 71 2011 5976 5986
13. E. Tibaldi Lyn-mediated SHP-1 recruitment to CD5 contributes to resistance to apoptosis of B-cell chronic lymphocytic leukemia cells Leukemia 25 2011 1768 1781
14. E.L. Mayer, and I.E. Krop Advances in targeting SRC in the treatment of breast cancer and other solid malignancies Clin. Cancer Res. 16 2010 3526 3532
15. T. Pene-Dumitrescu, and T.E. Smithgall Expression of a Src family kinase in chronic myelogenous leukemia cells induces resistance to imatinib in a kinase-dependent manner J. Biol. Chem. 285 2010 21446 21457
16. Y. Chen Are SRC family kinases responsible for imatinib- and dasatinib-resistant chronic myeloid leukemias? Leuk. Res. 35 2011 27 29
17. S. Hayette Longitudinal studies of SRC family kinases in imatinib- and dasatinib-resistant chronic myelogenous leukemia patients Leuk. Res. 35 2011 38 43
18. H. Yamazaki Regulation of cancer stem cell properties by CD9 in human B-acute lymphoblastic leukemia Biochem. Biophys. Res. Commun. 409 2011 14 21
19. R.B. Riggins Physical and functional interactions between Cas and c-Src induce tamoxifen resistance of breast cancer cells through pathways involving epidermal growth factor receptor and signal transducer and activator of transcription 5b Cancer Res. 66 2006 7007 7015 (Pubitemid 44197676)
20. T. van Agthoven Relevance of breast cancer antiestrogen resistance genes in human breast cancer progression and tamoxifen resistance J. Clin. Oncol. 27 2009 542 549
21. S. Hiscox Combining Src inhibitors and aromatase inhibitors: a novel strategy for overcoming endocrine resistance and bone loss Eur. J. Cancer 46 2010 2187 2195
22. L.F. Lee Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK Oncogene 23 2004 2197 2205
23. P. Mendiratta Genomic strategy for targeting therapy in castration-resistant prostate cancer J. Clin. Oncol. 27 2009 2022 2029
24. S. Zhang Combating trastuzumab resistance by targeting SRC, a common node downstream of multiple resistance pathways Nat. Med. 17 2011 461 469
25. M. Tan ErbB2 promotes Src synthesis and stability: novel mechanisms of Src activation that confer breast cancer metastasis Cancer Res. 65 2005 1858 1867 (Pubitemid 40478614)
26. Y. Nagata PTEN activation contributes to tumor inhibition by trastuzumab, and loss of PTEN predicts trastuzumab resistance in patients Cancer Cell 6 2004 117 127 (Pubitemid 39485684)
27. D. Mitra An oncogenic isoform of HER2 associated with locally disseminated breast cancer and trastuzumab resistance Mol. Cancer Ther. 8 2009 2152 2162
28. K. Liang Recombinant human erythropoietin antagonizes trastuzumab treatment of breast cancer cells via Jak2-mediated Src activation and PTEN inactivation Cancer Cell 18 2010 423 435
29. S.E. Wang Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton Cancer Res. 69 2009 475 482
30. J.P. Joshi Growth differentiation factor 15 (GDF15)-mediated HER2 phosphorylation reduces trastuzumab sensitivity of HER2-overexpressing breast cancer cells Biochem. Pharmacol. 82 2011 1090 1099
31. G. Zhuang Elevation of receptor tyrosine kinase EphA2 mediates resistance to trastuzumab therapy Cancer Res. 70 2010 299 308
32. B.N. Rexer Phosphoproteomic mass spectrometry profiling links Src family kinases to escape from HER2 tyrosine kinase inhibition Oncogene 30 2011 4163 4174
33. N.S. Nagaraj Combined blockade of Src kinase and epidermal growth factor receptor with gemcitabine overcomes STAT3-mediated resistance of inhibition of pancreatic tumor growth Clin. Cancer Res. 17 2011 483 493
34. R. Marcotte c-Src associates with ErbB2 through an interaction between catalytic domains and confers enhanced transforming potential Mol. Cell. Biol. 29 2009 5858 5871
35. D.L. Wheeler Epidermal growth factor receptor cooperates with Src family kinases in acquired resistance to cetuximab Cancer Biol. Ther. 8 2009 696 703
36. C. Li Nuclear EGFR contributes to acquired resistance to cetuximab Oncogene 28 2009 3801 3813
37. E.F. Dunn Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab Oncogene 30 2011 561 574
38. L. Bai Simultaneous targeting of src kinase and receptor tyrosine kinase results in synergistic inhibition of renal cell carcinoma proliferation and migration Int. J. Cancer 2011 10.1002/ijc.26303
39. A.A. Miller A phase II study of dasatinib in patients with chemosensitive relapsed small cell lung cancer (Cancer and Leukemia Group B 30602) J. Thorac. Oncol. 5 2010 380 384
40. Sharma, M.R. et al. Dasatinib in previously treated metastatic colorectal cancer: a phase II trial of the University of Chicago Phase II Consortium. Invest. New Drugs, doi:10.1007/s10637-011-9681-x (in press)
41. P.N. Lara Jr A phase II trial of the Src-kinase inhibitor AZD0530 in patients with advanced castration-resistant prostate cancer: a California Cancer Consortium study Anticancer Drugs 20 2009 179 184
42. S. Nallapareddy A phase II trial of saracatinib (AZD0530), an oral Src inhibitor, in previously treated metastatic pancreatic cancer ASCO Gastrointestinal Cancers Symposium 2010 2010 American Society of Clinical Oncology
43. M.G. Fury Phase II study of saracatinib (AZD0530) for patients with recurrent or metastatic head and neck squamous cell carcinoma (HNSCC) Anticancer Res. 31 2011 249 253
44. Mackay, H.J. et al. A phase II trial of the Src kinase inhibitor saracatinib (AZD0530) in patients with metastatic or locally advanced gastric or gastro esophageal junction (GEJ) adenocarcinoma: a trial of the PMH phase II consortium. Invest. New Drugs, doi:10.1007/s10637-011-9650-4 (in press)
45. A. Gucalp Phase II Trial of saracatinib (azd0530), an oral Src-inhibitor for the treatment of patients with hormone receptor-negative metastatic breast cancer Clin. Breast Cancer 11 2011 306 311
46. Campone, M. et al. Phase II study of single-agent bosutinib, a Src/Abl tyrosine kinase inhibitor, in patients with locally advanced or metastatic breast cancer pretreated with chemotherapy. Ann Oncol., doi:10.1093/annonc/ mdr261 (in press)
47. J.J. Arcaroli Gene array and fluorescence in situ hybridization biomarkers of activity of saracatinib (AZD0530), a Src inhibitor, in a preclinical model of colorectal cancer Clin. Cancer Res. 16 2010 4165 4177
48. N.S. Nagaraj Targeted inhibition of SRC kinase signaling attenuates pancreatic tumorigenesis Mol. Cancer Ther. 9 2010 2322 2332
49. N. Suwaki A HIF-regulated VHL-PTP1B-Src signaling axis identifies a therapeutic target in renal cell carcinoma Sci. Transl. Med. 3 2011 85ra47
50. W. Okamoto Identification of c-Src as a potential therapeutic target for gastric cancer and of MET activation as a cause of resistance to c-Src inhibition Mol. Cancer Ther. 9 2010 1188 1197
51. J.H. Ahn, and M. Lee Suppression of autophagy sensitizes multidrug resistant cells towards Src tyrosine kinase specific inhibitor PP2 Cancer Lett. 310 2011 188 197
52. Y. Chen Combined Src and ER blockade impairs human breast cancer proliferation in vitro and in vivo Breast Cancer Res. Treat. 128 2011 69 78
53. Y. Chen Combined Src and aromatase inhibition impairs human breast cancer growth in vivo and bypass pathways are activated in AZD0530-resistant tumors Clin. Cancer Res. 15 2009 3396 3405
54. E.B. Haura Phase I/II study of the Src inhibitor dasatinib in combination with erlotinib in advanced non-small-cell lung cancer J. Clin. Oncol. 28 2010 1387 1394
55. F.M. Johnson Phase II study of dasatinib in patients with advanced non-small-cell lung cancer J. Clin. Oncol. 28 2010 4609 4615
56. A. Bertotti Inhibition of Src impairs the growth of met-addicted gastric tumors Clin. Cancer Res. 16 2010 3933 3943
57. B. Sen Distinct interactions between c-Src and c-Met in mediating resistance to c-Src inhibition in head and neck cancer Clin. Cancer Res. 17 2011 514 524
58. T. Yoshida Effects of Src inhibitors on cell growth and epidermal growth factor receptor and MET signaling in gefitinib-resistant non-small cell lung cancer cells with acquired MET amplification Cancer Sci. 101 2010 167 172
59. K.L. Mueller Met and c-Src cooperate to compensate for loss of epidermal growth factor receptor kinase activity in breast cancer cells Cancer Res. 68 2008 3314 3322
60. E.L. Mayer A Phase 2 trial of dasatinib in patients with advanced HER2-positive and/or hormone receptor-positive breast cancer Clin. Cancer Res. 17 2011 6897 6904